Eli Lilly notches unexpected Q2 gains in China and Japan on volumes

Lilly

China and Japan were unexpected bright spots for Eli Lilly ($LLY) as it provided an upbeat forecast to the end of the decade on the July 26 earnings call in what can now be seen as a swan song for chief John Lechleiter as he moves to relinquish the roles as chairman, president and CEO at the end of 2016.

On the first quarter earnings call Lechleiter voiced caution on the Japan market--its largest outside the U.S. and a consistent performer--as a series of reimbursement price cuts took hold.

The company did win a nod for two new indications of Cyramza (ramucirumab) in the second quarter for metastatic colorectal and non-small cell lung cancer as well as approval for Taltz (ixekizumab) to treat psoriasis and psoriatic arthritis, Lechleiter noted.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

But the macro picture on prices in Japan had Lechleiter "very concerned" in the first quarter, which may have been a bit too worried as volumes offset the impact of the cuts going by the figures presented by Phil Johnson, head of Investor Relations

"In Japan, pharma revenue increased 21% in total, driven by mid-teens volume growth and an 11% benefit from a stronger yen, partially offset by a 7% negative price effect from the latest biannual price cuts," Johnson said on the call.

"On a constant currency basis, Japan pharma revenue increased 10%. This performance growth was attributable to a number of products, led by Cyramza, but also including Cymbalta (duloxetine), Strattera (atomoxetine), Basaglar (insulin glargine), Trulicity (dulaglutide)‎ and Tradjenta (linagliptin)."

The company also expects to file for rheumatoid arthritis candidate baricitinib (LY3009104) in Japan next year, Lechleiter said.

And while Johnson had more downbeat news on emerging markets overall--revenues down 3% in the second quarter on a stronger dollar--China provided a bright spot after a 14% drop in the first quarter, or 9% on a constant-currency basis.

"Our pharma revenue in China increased 15%, or 23% on a constant currency basis," Johnson said on the call.

"This quarter's growth rate did benefit from customer buying patterns in both last year's quarter and this quarter. We estimate that underlying demand for our products in China increased 5% in the second quarter."

- here's the release

Related Articles:
Changing of the guard at Lilly: CEO Lechleiter to step down at year's end, and SVP Ricks will step up
Fresh off a 9% quarterly sales hike, Lilly sees new launches driving solid growth through 2020
Lilly shines in Japan in Q1, but CEO warns price cuts too deep

Read more on

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.